Literature DB >> 2175382

Basic mechanisms in vascular headache.

M A Moskowitz1.   

Abstract

To better understand and treat painful conditions, one needs to identify the cause, discover the source, and develop knowledge of peripheral and central pain transmission; headaches are no exception. The development of appropriate animal models is important. Accordingly, we have reviewed the anatomy, neurochemistry, electrophysiology, and pharmacology of the trigeminovascular system in experimental animals and emphasized whenever possible the relevance of this final common pathway to migraine, cluster, and other headache syndromes in humans. For example, based on recent anatomic dissections, the pericarotid cavernous sinus plexus was suggested as an important focus to investigate cluster headache pathophysiology. This plexus is an anatomic point of convergence for the nerves giving rise to the signs of sympathetic and parasympathetic activity and sensory symptoms that develop in cluster patients. As in other nociceptive systems, trigeminovascular axons assume at least two important roles. One concerns the transmission of nociceptive information. Electrophysiologic evidence supports the trigeminal nucleus caudalis as an important site for the convergence of visceral (vessel) and somatic (forehead) inputs to mediate the referral of vascular pain to superficial tissues. A second important role concerns the initiation of local increases in blood flow and enhanced protein permeability (sterile inflammation) via the axonal release of vasoactive neuropeptides. Plasma extravasation develops within the dura mater following trigeminal stimulation. Extravasation can be blocked by the administration of ergot alkaloids or sumatriptan, a new serotonin-like agonist, and a prejunctional (neuronal) mechanism of action for these drugs (such as blockade of release) was suggested based on experimental evidence. Whether vasoconstriction also relates to the therapeutic efficacy remains to be determined. As in other organ systems, real or threatened tissue injury provides an important stimulus for depolarizing sensory fibers. The stimulus may come from external conditions such as reduced blood flow or hypoglycemia. The brain may also possess intrinsic neuronal mechanisms by which nociceptors may be synthesized (e.g., glutamate-induced neurotoxicity, seizures). Molecules of relevance include bradykinin, prostaglandins, leukotrienes, and potassium. Experimental evidence was presented demonstrating that the trigeminal nerve mediates hyperemia within cortical gray matter by axon-reflex like mechanisms. An important role for this nerve was established during the hyperemic period of recirculation after ischemia or during severe hypertension above the limits of autoregulation.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Year:  1990        PMID: 2175382

Source DB:  PubMed          Journal:  Neurol Clin        ISSN: 0733-8619            Impact factor:   3.806


  48 in total

1.  Therapy of Migraine Headache in Cancer Patients.

Authors: 
Journal:  Curr Rev Pain       Date:  1999

2.  Progressive ataxia due to a missense mutation in a calcium-channel gene.

Authors:  Q Yue; J C Jen; S F Nelson; R W Baloh
Journal:  Am J Hum Genet       Date:  1997-11       Impact factor: 11.025

Review 3.  Animal models of chronic migraine.

Authors:  Robin James Storer; Weera Supronsinchai; Anan Srikiatkhachorn
Journal:  Curr Pain Headache Rep       Date:  2015-01

4.  Melatonin treatment decreases c-fos expression in a headache model induced by capsaicin.

Authors:  Fabiano C Tanuri; Eliângela de Lima; Mario F P Peres; Francisco R Cabral; Maria da Graça Naffah-Mazzacoratti; Esper Abrão Cavalheiro; José Cipolla-Neto; Eliova Zukerman; Débora Amado
Journal:  J Headache Pain       Date:  2009-01-27       Impact factor: 7.277

5.  Association between Chlamydia pneumoniae IgG antibodies and migraine.

Authors:  QiHong Lu; Jinzh Xu; HongYan Liu
Journal:  J Headache Pain       Date:  2009-02-24       Impact factor: 7.277

6.  Migraine Headache: Immunosuppressant Therapy.

Authors:  Todd D. Rozen
Journal:  Curr Treat Options Neurol       Date:  2002-09       Impact factor: 3.598

7.  Rofecoxib versus ibuprofen for acute treatment of migraine: a randomised placebo controlled trial.

Authors:  U K Misra; M Jose; J Kalita
Journal:  Postgrad Med J       Date:  2004-12       Impact factor: 2.401

8.  Cerebral microcirculatory responses of insulin-resistant rats are preserved to physiological and pharmacological stimuli.

Authors:  Adam Institoris; Laura Lenti; Ferenc Domoki; Edina Wappler; Tamás Gáspár; Prasad V Katakam; Ferenc Bari; David W Busija
Journal:  Microcirculation       Date:  2012-11       Impact factor: 2.628

9.  Activity of botulinum toxin type A in cranial dura: implications for treatment of migraine and other headaches.

Authors:  Zdravko Lacković; Boris Filipović; Ivica Matak; Zsuzsanna Helyes
Journal:  Br J Pharmacol       Date:  2016-01       Impact factor: 8.739

Review 10.  Migraine pathogenesis and state of pharmacological treatment options.

Authors:  Till Sprenger; Peter J Goadsby
Journal:  BMC Med       Date:  2009-11-16       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.